Brief: Simcere Pharmaceutical Says FY Profit Attributable RMB715 Mln
20/03/2024 15:13
March 20 (Reuters) - Simcere Pharmaceutical Group Ltd
2096.HK :
* FY PROFIT ATTRIBUTABLE RMB715 MILLION, DECREASE OF 23.2%
* REVENUE OF GROUP FOR FY RMB6,608 MILLION, INCREASE OF 4.5%
* DECLARED FINAL DIVIDEND OF RMB0.16 PER SHARE
Further company coverage: 2096.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Simcere Pharmaceutical
See all newsBrief: Simcere Pharmaceutical Announces Approval For Marketing Of Yingmule In China By NMPA
Simcere Pharmaceutical jumps most in two months on Roche tie-up
Roche signs global licensing pact for Simcere's experimental blood cancer drug (updated)
Roche signs global licensing pact for Simcere's B-cell cancer drug candidate
Brief: Simcere Pharmaceutical Enters Exclusive Global Licensing Agreement With Roche For SIM0660